MR Imaging–guided Focal Laser Ablation for Prostate Cancer: Phase I Trial
- 1 June 2013
- journal article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 267 (3), 932-940
- https://doi.org/10.1148/radiol.13121652
Abstract
Purpose To evaluate the feasibility and safety of magnetic resonance (MR) imaging–guided laser-based thermotherapy in men with clinically low-risk prostate cancer and a concordant lesion at biopsy and MR imaging. Materials and Methods This HIPAA-compliant phase I prospective study was approved by the institutional review board. Informed consent was obtained from all patients. Transperineal MR imaging–guided focal laser ablation for clinically low-risk prostate cancer was performed in patients with a Gleason score of 7 or less in three or fewer cores limited to one sextant obtained with transrectal ultrasonography (US)-guided biopsy and a concordant lesion at MR imaging. Lesions were targeted with a laser ablation system. Periprocedural complications were recorded. The International Prostate Symptom Score (IPSS) and the Sexual Health Inventory for Men (SHIM) score were collected before and after the procedure. MR imaging–guided biopsy of the ablation zone was performed 6 months after treatment. The prostate-specific antigen level, IPSS, and SHIM score before and after ablation were compared by using the Wilcoxon signed rank test. Results Treatment was successfully completed in nine patients (procedure duration, 2.5–4 hours; mean laser ablation duration, 4.3 minutes). Immediate contrast-enhanced posttreatment MR imaging showed a hypovascular defect in eight patients. Self-resolving perineal abrasion and focal paresthesia of the glans penis each occurred in one patient. The mean (±standard deviation) IPSS and SHIM score at baseline were 5.8 ± 5.3 and 19.0 ± 8.0, respectively. Average score changes were not significantly different from zero during follow-up (P = .18–.99). MR imaging–guided biopsy of the ablation zone showed no cancer in seven patients (78%) and Gleason grade 6 cancer in two (22%). Conclusion Transperineal MR imaging–guided focal laser ablation appears to be a feasible and safe focal therapy option for clinically low-risk prostate cancer. © RSNA, 2013 Supplemental material: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.13121652/-/DC1This publication has 19 references indexed in Scilit:
- Predicting 15-Year Prostate Cancer Specific Mortality After Radical ProstatectomyJournal of Urology, 2011
- Magnetic Resonance Guided, Focal Laser Induced Interstitial Thermal Therapy in a Canine Prostate ModelJournal of Urology, 2010
- Focal Therapy for Prostate Cancer: Possibilities and LimitationsEuropean Urology, 2010
- Photodynamic therapy for focal ablation of the prostateWorld Journal of Urology, 2010
- Focal Cryotherapy for Prostate CancerCurrent Urology Reports, 2010
- Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate CancerJournal of Clinical Oncology, 2010
- Quality of Life and Satisfaction with Outcome among Prostate-Cancer SurvivorsThe New England Journal of Medicine, 2008
- Irreversible Electroporation: A New Ablation Modality — Clinical ImplicationsTechnology in Cancer Research & Treatment, 2007
- 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experienceInternational Journal of Radiation Oncology*Biology*Physics, 2007
- Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate CancerJNCI Journal of the National Cancer Institute, 2003